Group 1 - The company, Meizhong Jiahe (02453), has completed the placement of shares as per the terms of the placement agreement on July 29, 2025 [1] - A total of 48.7236 million shares were successfully placed at a price of HKD 5.54 per share, which represents approximately 18.38% of the issued H shares prior to completion and about 6.63% of the total issued shares [1] - Following the completion of the placement, the newly issued shares will account for approximately 15.52% of the total issued H shares and about 6.22% of the total issued shares [1]

格隆汇7月29日丨美中嘉和(02453.HK)公告，董事会欣然宣布，配售协议所载全部条件已获达成且配售 事项已于2025年7月29日按照配售协议的条款及条件完成。于本公告日期，合共4872.36万股配售股份已 由配售代理根据配售协议的条款及条件按每股配售股份5.54港元配售价向不少于六名承配人成功配售， 相当于紧接完成前已发行H股数目的约18.38%及已发行股份数目的约6.63%，以及紧随完成后经配发及 发行配售股份扩大后已发行H股数目的约15.52%及已发行股份数目的约6.22%。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 美中嘉和醫學技術發展集團股份有限公司 呈交日期： 2025年7月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02453 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 本公告不會於美國或其境內直接或間接分發。本公告並不構成或組成於美國購買或認購證券之 任何要約或招攬之一部分。本公告所述之本公司股份並未亦將不會根據1933年美國證券法（經 修訂）（「證券法」）登記，且除非已根據證券法之登記規定登記或獲豁免登記，否則將不得於美 國提呈發售或出售。本公司股份將不會於美國公開發售。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 董事會欣然宣佈，配售協議所載全部條件已獲達成且配售事項已於2025年7月29 日按照配售協議的條款及條件完成。於本公告日期，合共48,723,600股配售股份 已由配售代理根據配售協議的條款及條件按每股配售股份5.54港元之配售價向不 少於六名承配人成功配售，相當於緊接完成前已發行H股數目的約18.38%及已發 行股份數目的約 ...

Market Overview - The Hong Kong stock market showed volatility, with the Hang Seng Index closing at 25,130.03 points, up 0.54% or 135.89 points, with a total turnover of HKD 266.07 billion [1] - The Hang Seng China Enterprises Index rose 0.39% to 9,075.6 points, while the Hang Seng Tech Index increased by 0.38% to 5,606.83 points [1] Blue Chip Performance - BYD (01211) saw a significant increase of 5.09%, closing at HKD 134.2, contributing 37.78 points to the Hang Seng Index [2] - In the first half of 2023, BYD's domestic sales exceeded 2.113 million units, a year-on-year increase of 31.5%, while overseas sales reached 472,000 units, up 128.5% [2] - Other notable blue chips included Xinyi Glass (00868) up 7.23%, Zhongsheng Holdings (00881) up 6.15%, while New Oriental (09901) and Bank of China Hong Kong (02388) saw declines of 4.92% and 3.5% respectively [2] Sector Highlights - Coal stocks surged, with Mongolian Coking Coal (00975) up 11.55% and Yancoal Australia (01171) up 9.53%, driven by rumors of capacity control measures in the coal industry [3][4] - Infrastructure stocks performed strongly, with China Communications Construction (01800) rising 7.57% and China Railway Construction (01186) up 6.03% [4] - The launch of the Yarlung Tsangpo River downstream hydropower project, with an investment of approximately CNY 1.2 trillion, is expected to boost infrastructure investment [5] Commodity and Material Stocks - Non-ferrous metal stocks continued to rise, with Ganfeng Lithium (01772) up 8.94% and Luoyang Molybdenum (03993) up 7.12%, supported by upcoming policies aimed at stabilizing growth in key industries [6] - The photovoltaic sector was active, with Kaisa New Energy (01108) rising 8% and GCL-Poly Energy (03800) up 6.67%, as supply-side reforms are anticipated to improve industry conditions [7] Notable Stock Movements - China Longgong (03339) surged 15.83% after announcing a significant profit increase forecast for the first half of 2025 [8] - Fufeng Group (00546) rose 10.8% on expectations of a substantial profit increase due to higher sales and lower raw material costs [9] - Lijun Pharmaceutical (01513) reached a new high, up 9.37%, following positive clinical trial results for a new drug [10] - Harbin Electric (01133) climbed 8.14% after announcing a profit forecast that exceeded expectations [11] - Meizhong Jiahe (02453) faced pressure, down 6%, due to a planned share placement at a discount [12]

Group 1: Market Developments - Hong Kong Stock Exchange will lower the minimum price fluctuation for stocks starting August 4, 2025, following successful market rehearsals and regulatory approvals [1] - The Hang Seng Index's ADR closed at 24,987.99 points, down 6.15 points or 0.02% [3] Group 2: Index Adjustments - The Hang Seng Index announced changes to the calculation method of the Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index, effective from the index review on June 30, 2025 [2] Group 3: Company Earnings - Cathay Pacific reported a 23.3% year-on-year increase in passenger numbers, carrying approximately 2.9 million passengers in June 2025 [8] - China Longgong expects a significant increase in net profit for the first half of 2025, estimated between RMB 590 million and RMB 665 million, representing a year-on-year increase of 29% to 45% [11] - Meitu Company anticipates a 65% to 72% year-on-year growth in adjusted net profit for the first half of 2025 [10] - Hengtou Securities expects a net profit of approximately RMB 239 million for the first half of 2025, a significant increase from RMB 53.87 million in the same period last year [14] - Huiri Group forecasts a consolidated profit of approximately HKD 250 million for the first half of 2025, up from HKD 37 million in the previous year [15] - Harbin Electric anticipates a net profit of approximately RMB 1.02 billion for the first half of 2025, a substantial increase from RMB 523 million in the same period last year [21] Group 4: Strategic Initiatives - Multiple departments released implementation details for cross-border asset management pilot business in Hainan Free Trade Port, allowing foreign investors to invest in various financial products [6] - Dongyangguang Jiangsu Pharmaceutical and Dongyangguang Pharmaceutical's merger agreement was approved by shareholders, with the new entity expected to be listed on August 7, 2025 [13] - Global New Materials International's acquisition of Merck's surface solutions business was approved by a special shareholder meeting, with a transaction value of EUR 665 million [17] Group 5: Industry Trends - GGII reported that China's power battery installation capacity reached approximately 288.1 GWh in the first half of 2025, a year-on-year increase of 44% [5] - The key product DB-1310 from InnoCare Pharma has received fast track designation from the FDA for treating advanced non-small cell lung cancer [20]

Group 1 - The core announcement is that Meizhong Jiahe plans to raise approximately HKD 270 million through the placement of 48,723,600 new H shares, with a net amount of about HKD 260 million after expenses [1] - The placement price is set at HKD 5.54 per share, representing a discount of approximately 16.9% to the closing price of HKD 6.67 on July 21, 2025, and a discount of about 19.9% to the average closing price of HKD 6.92 over the previous five trading days [1] - The newly issued shares will account for approximately 6.6% of the existing issued share capital and about 6.2% of the enlarged share capital after the placement [1] Group 2 - The funds raised will be allocated for the construction of Shanghai Taihe Cheng Cancer Hospital, support for medical AI business needs, repayment of financial institution loans, and to supplement working capital [1] - The issuance is conducted under a general mandate granted by the shareholders' meeting and is expected to be completed on the second business day after obtaining listing approval, no later than July 29, 2025 [1]

Core Viewpoint - 美中嘉和 (02453.HK) has entered into a placement agreement with Guotai Junan International to issue 48.72 million shares at a price of HKD 5.54 per share, representing approximately 18.38% of the existing H shares and 6.63% of the total issued shares as of the announcement date [1][2] Group 1: Placement Details - The placement involves 48.72 million shares, which will be issued under a general authorization [1] - The placement shares will account for approximately 15.52% of the enlarged issued H shares and about 6.22% of the total issued shares after the placement [1] Group 2: Use of Proceeds - The total expected proceeds from the placement are approximately HKD 270 million, with a net amount of about HKD 259 million [2] - The net proceeds will be allocated as follows: - Approximately HKD 77.63 million (30%) for the construction of Shanghai Taihe Cheng Tumor Hospital, expected to be fully utilized by June 30, 2026 [2] - Approximately HKD 38.82 million (15%) to support the company's medical AI business, including operational and R&D expenses, also expected to be fully utilized by June 30, 2026 [2] - Approximately HKD 64.69 million (25%) for repaying loans from financial institutions, including principal and interest for working capital loans and fixed asset loans, expected to be fully utilized by June 30, 2026 [2] - Approximately HKD 77.63 million (30%) for replenishing the company's working capital and general corporate purposes, expected to be fully utilized by June 30, 2026 [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 本公告不會於美國或其境內直接或間接分發。本公告並不構成或組成於美國購買或認購證券之 任何要約或招攬之一部分。本公告所述之本公司股份並未亦將不會根據1933年美國證券法（經 修訂）（「證券法」）登記，且除非已根據證券法之登記規定登記或獲豁免登記，否則將不得於美 國提呈發售或出售。本公司股份將不會於美國公開發售。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 根據一般授權按配售協議配售新股份 獨家整體協調人、配售代理及資本市場中介人 於2025年7月22日（交易時段前），本公司與配售代理訂立配售協議。據此，配 售代理已有條件同意擔任本公司獨家配售代理，並以盡最大努力基準促使不少 於六(6)名承配人（該等承配人及其最 ...

Core Viewpoint - Meizhong Jiahe (2453.HK) has achieved a significant breakthrough in the treatment of choroidal malignant melanoma by successfully completing the first proton therapy in China, which preserves the patient's eye and vision, filling a treatment gap in the country [1][2]. Group 1: Treatment Innovation - The proton therapy using "pencil beam scanning" technology allows for high-dose radiation to be precisely focused on the tumor while minimizing damage to surrounding critical structures, marking a shift from destructive to functional treatment [1][2]. - Traditional treatment methods primarily involved enucleation, which resulted in permanent blindness and facial disfigurement for patients [1]. Group 2: Patient Outcomes - The first patient treated, a 45-year-old male from Hunan, experienced a significant improvement in vision from 0.1 to 0.4 within 48 hours post-treatment, with tumor markers decreasing by 90% and no complications such as corneal ulcers or retinal detachment [2]. - The patient expressed satisfaction with the treatment, stating he was able to retain his eye and continue working, contrasting with his initial expectation of undergoing enucleation [2]. Group 3: Market Potential - Proton therapy is recommended as a first-line treatment for choroidal melanoma in the 2024 NCCN guidelines, providing evidence-based support for eye-preserving strategies [2]. - With approximately 2,500 new cases of choroidal malignant melanoma diagnosed annually in China, Meizhong Jiahe's advancements in this field are expected to benefit domestic patients and create substantial market opportunities for the company [2].